Wall Street Zen upgraded shares of Accuray (NASDAQ:ARAY – Free Report) to a hold rating in a research note published on Saturday,Wall Street Zen reports.
Separately, Weiss Ratings lowered shares of Accuray from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 1st. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Accuray has a consensus rating of “Reduce”.
Get Our Latest Analysis on Accuray
Accuray Stock Performance
Accuray (NASDAQ:ARAY – Get Free Report) last released its earnings results on Wednesday, August 19th. The medical equipment provider reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.40. Accuray had a negative return on equity of 35.36% and a negative net margin of 4.41%. The business had revenue of $100.92 million for the quarter, compared to analyst estimates of $105.30 million.
Institutional Investors Weigh In On Accuray
Institutional investors have recently added to or reduced their stakes in the business. Weber Capital Management LLC ADV acquired a new position in shares of Accuray during the 2nd quarter worth approximately $1,271,652. BlackRock Inc. purchased a new stake in Accuray in the 2nd quarter valued at approximately $842,000. Squarepoint Ops LLC grew its holdings in Accuray by 164.7% during the 2nd quarter. Squarepoint Ops LLC now owns 1,448,234 shares of the medical equipment provider’s stock valued at $373,000 after buying an additional 901,158 shares during the last quarter. Susquehanna International Group LLP grew its holdings in Accuray by 2,344.3% during the 2nd quarter. Susquehanna International Group LLP now owns 825,604 shares of the medical equipment provider’s stock valued at $213,000 after buying an additional 791,827 shares during the last quarter. Finally, Ieq Capital LLC purchased a new position in Accuray during the second quarter worth $86,000. Hedge funds and other institutional investors own 64.08% of the company’s stock.
About Accuray
Accuray Incorporated develops, manufactures, and sells radiation therapy systems and related software for treating cancer and other conditions. Its technologies are used by hospitals and cancer treatment centers to plan and deliver radiation treatments. The company’s products include the CyberKnife platform, a robotic system designed to deliver stereotactic radiosurgery and radiation therapy, and the Radixact platform, which uses helical tomotherapy to deliver image-guided radiation treatments. Accuray also provides treatment-planning software, service, and support for its systems.
See Also
- Five stocks we like better than Accuray
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.
